Trident Lifeline Ltd Management Discussions

Global Economy

The global economy in 2025-26 has been defined by steady but uneven growth
alongside renewed geopolitical stress. Global growth is projected at 3.3% for 2026 and
3.2% for 2027, broadly in line with the estimated 3.3% outturn for 2025. This resilience
reflects a balancing of divergent forces: headwinds from shifting trade and tariff
policies offset by investment linked to technology, particularly artificial intelligence,
together with accommodative financial conditions and private-sector adaptability.

The 2026 global forecast was
subsequently trimmed to
around 3.1%, reflecting the
intensification of conflict in the
Middle East and related energy-
market risks.

Estimates for the year vary
with the assessment of these
energy-market effects, with
more cautious forecasts
placing 2026 growth closer
to 2.5% on the back of higher
energy prices linked to the
Middle East conflict. Even so,
the underlying momentum
has held: easing inflation,
resilient labour markets in
several major economies, and
a strong investment cycle in
technology have cushioned
the impact of trade friction.

The principal downside risks
remain geopolitical escalation,
disruption of energy supply
routes such as the Strait of
Hormuz, and commodity-
market volatility, and these
warrant monitoring rather
than signalling a change in the
broad trajectory.

Inflation has continued
to moderate across most
economies, allowing many
central banks to ease policy,
and this shift toward lower
rates is expected to support
demand as the year progresses.
Among advanced economies,
growth remains modest, with
the United States expanding
at a below-trend pace and the
Euro Area and Japan slower
still, while emerging Asia
continues to anchor global
expansion. On balance, the
picture is one of steady, resilient
growth alongside elevated
uncertainty, where continued
policy discipline should help
preserve stability.

Source: IMF (January and April 2026
World Economic Outlook); World
Bank (Global Economic Prospects,
2026).

Indian Economy

India remained the fastest-
growing major economy
through FY26. The estimate for
the year ending March 2026 was
raised to approximately 7.4%,
above the earlier projection
band of 6.3% to 6.8%, supported
by a strong third quarter in
which GDP grew 8.2% year-on-
year. Indias fiscal-year growth
is correspondingly estimated at
around 7.3%, reflecting stronger-
than-expected momentum
in the second half of the year.
Growth is expected to moderate
to a still-robust 6.4% to 6.5% over
the following two fiscal years as
cyclical tailwinds fade, with FY27
growth placed at 6.5%.

This resilience continues to rest
on solid domestic fundamentals:
strong private consumption, a
rising working-age population,
a revitalised manufacturing
base, and sustained public
investment in infrastructure.
Inflation has returned to near
the Reserve Bank of Indias
target after a marked decline
through 2025, aided by subdued
food prices, which in turn
supports household demand.

Indias nominal GDP now places
it among the worlds largest
economies, and its contribution
to incremental global growth
continues to rise.

The outlook is not without
headwinds. External risks include
global trade friction, the recent
escalation of United States tariff
measures on Indian goods,
geopolitical instability in the
Middle East, and the associated
energy-price and currency
pressures. Continued policy
calibration is advised to balance
growth and inflation, rebuild
fiscal and monetary buffers,
and advance structural reforms
that raise investment and
productivity. On balance, Indias
growth trajectory, supported
by favourable demographics
and reform momentum, keeps
it positioned as a leading driver
of the global economy, while
sustained progress will depend
on vigilant policy management
and proactive risk mitigation.

Source: IMF (January and April 2026
World Economic Outlook); National
Statistics Office; Reserve Bank
of India

Global Pharmaceutical
Industry

The global pharmaceutical
industry is undergoing a
structural transformation driven
by technological convergence
and strategic realignment.
Industry assessments continue
to point to a healthy medium-
term growth path, with
outlooks indicating a CAGR of
around 7.1% between 2024 and
2030, a marked recovery from
the plateau seen when biologics
slowed and COVID-19 vaccine
demand fell. Growth patterns
remain differentiated by region:
developed markets such as the
United States and Europe are
expanding more moderately
amid evolving pricing and
regulatory frameworks, while
emerging markets across Asia-
Pacific, Latin America, and
other regions grow faster, with
Asia-Pacific leading.

Several forces are reshaping
the sector. Supply-chain
regionalisation has become a
strategic priority as companies
move toward regional suppliers
to reduce geopolitical exposure
and improve reliability. The
sector also faces significant

near-term patent expirations
that place substantial revenue
at risk, making portfolio renewal
and supply-chain optimisation
urgent. Environmental, social,
and governance commitments
are influencing manufacturing
strategy, with rising investment
in green-chemistry initiatives
and sustainable operations.
Artificial intelligence and
digitalisation are accelerating
across drug discovery, clinical-
trial design, and manufacturing,
while precision medicine and
personalised healthcare are
gaining momentum on the
back of advances in genomic
sequencing and digital health.
Overall, the industrys ability
to adopt new technologies,
optimise supply chains, and
develop targeted therapies
positions it for sustained growth
despite macroeconomic and
policy headwinds.

Source: Frost & Sullivan Global
Pharmaceutical Industry Outlook;
industry analyses (2025-2026).
Market-research estimates.

Indian

Pharmaceutical

Industry

India retained its standing
as the third-largest
pharmaceutical producer by
volume and thirteenth by
value, supported by more than
3,000 companies and around
10,500 manufacturing units.
The domestic pharmaceutical
market was valued at
approximately USD 50 billion
in FY24, and the sectors stated
ambition is to grow it from
around USD 60 billion currently
toward USD 130 billion by 2030
and USD 450 billion by 2047.
Independent market forecasts
are more conservative,
estimating the market at about
USD 60.32 billion in 2026 and

USD 79.74 billion by 2031, a
CAGR of approximately 5.74%.

Export performance in FY26
was steadier than in the prior
year. Drug and pharmaceutical
exports reached approximately
USD 31.11 billion (about Rs.2.74
lakh crore), an increase of
roughly 2.1% over FY25s USD
30.47 billion. The more muted
dollar growth reflected, in part,
elevated FY25 procurement
in the United States ahead of
tariff changes, which raised
the prior-year base, alongside
currency movements; growth
in rupee terms was firmer.

India continues to supply
around 20% of global generic
demand by volume, including
a substantial share of United
States and United Kingdom

requirements, with a majority
of exports directed to highly
regulated markets.

Domestically, sector revenue
growth of 7% to 9% was
projected for FY26, with the
home market expanding 8%
to 10% on the back of sales-
force expansion, wider rural
reach, and new launches,
while chronic therapies
continued to outpace acute
segments. Growth was more
measured in the United States,
where pricing pressure and
regulatory scrutiny weighed
on realisations, and stronger
in Europe.

Policy support remained
a defining feature of the
year, delivered through the
following measures:

-Production-Linked Incentive
(PLI) scheme: a total outlay
of Rs.15,000 crore (about USD
2.04 billion) spanning 2020-
21 to 2028-29 to strengthen
domestic manufacture and
product diversification.

-Biopharma SHAKTI initiative:
a Rs.10,000 crore scheme
announced in early 2026 to
build a competitive domestic
ecosystem for biologics and
biosimilars and reduce import
dependence.

-API push: a Rs.60,000 crore
(about USD 7 billion)
programme announced in
December 2025 to expand
domestic manufacture of active
pharmaceutical ingredients
and cut import reliance.

-PRIP scheme: the Promotion
of Research and Innovation
in Pharma MedTech Sector
programme, strengthening
research and development
capability.

-Jan Aushadhi network: 16,912
Pradhan Mantri Bhartiya
Janaushadhi Kendras
operational as of mid-2025,
targeting 25,000 by March
2027, improving access to
affordable generics.

-Trade agreements: free-trade
pacts concluded with the
European Union, the United
Kingdom, and New Zealand,
aimed at enhancing market
access and reducing tariffs for
pharmaceuticals and medical
devices.

Foreign direct investment
continued to flow into the
sector, reflecting confidence
in Indias manufacturing
ecosystem, and quality
and compliance standards
continued to strengthen.

The sectors cost advantage,
regulatory maturity, and
expanding reach across more
than 200 markets support
its continued transition from
a volume-led model toward
higher-value segments
including biosimilars,
specialty medicines, and
complex generics.

Source: IBEF; Economic
Survey 2025-26; ICRA; Mordor
Intelligence; Ministry of
Commerce and Industry (2025-
2026).

Global Nutraceutical
Industry

The global nutraceutical
industry continues to expand
as consumers shift from
reactive treatment toward
proactive health management.
The market was valued at
approximately USD 636 billion
in 2025 and is estimated at
around USD 684 billion in
2026, with projections to
reach roughly USD 1,151
billion by 2033 at a compound
annual growth rate (CAGR)
of about 7.7%. Its evolution
from a niche category into a
mainstream health solution,
bridging conventional food and
pharmaceutical intervention,
remains the defining
structural trend.

Rising health consciousness is
the primary driver, reinforced
by the growing prevalence
of lifestyle-related conditions

such as obesity, diabetes,
and cardiovascular disease,
and by ageing populations in
developed markets seeking
support for joint, cognitive, and
cardiovascular health. Product
diversification across functional
foods, functional beverages,
and dietary supplements
continues to reshape the
category. Dietary supplements
retain the largest product share,
while functional beverages are
among the fastest-growing
segments, favoured for
their convenience.

Regionally, Asia-Pacific
dominates, accounting
for close to 39% of global
revenue in 2025, supported
by rising disposable incomes,
health awareness, ageing
demographics, and a strong
cultural affinity for traditional
medicine. Clean-label and
sustainability trends are
reshaping formulation and

sourcing, with growing demand
for natural, plant-based
ingredients including botanicals
such as ashwagandha and
turmeric. Innovation in delivery
formats, spanning gummies,
powders, fortified snacks,
and beverages, is improving
consumer compliance and
broadening reach, particularly
among younger demographics.
Continued investment in
scientific validation and
regulatory compliance is
establishing nutraceuticals
as credible, evidence-based
health solutions.

Source: Grand View Research;
Fortune Business Insights; Mordor
Intelligence (2025-2026). Market-
research estimates.

Company Overview

Trident Lifeline Limited has
established itself as a growing
force in the pharmaceutical
industry, distinguished by
a focus on innovation and
disciplined expansion. Founded
in 2014, the Company operates
a hybrid business model that
combines its own and contract
manufacturing with direct
exports, allowing it to scale
efficiently and serve diverse
geographies including India,
Africa, Latin America, the CIS
region and Asia. Its product
portfolio spans key therapeutic
areas including anti-bacterial,
anti-diabetic, anti-hypertensive,
anti-lipidemic, proton pump
inhibitor and nutraceutical
categories, alongside cosmetic
and herbal products through
its subsidiaries.

During FY26, the Company continued to strengthen its
group structure. Its principal subsidiaries and holdings are:

51% Ownership TNS Pharma Private Limited: Manufactures tablets, capsules and dry powder suspensions.	51% Ownership TLL Wellness Limited: Operates across herbal products and nutraceutical supplements.
60%	100%
Ownership	Ownership
Trident Mediquip Limited:	TLL Elements
Operates across medical	Private Limited:
devices, including IV cannulas	Manufactures, trades
and Air Block Mechanism	and distributes skin and
Infusion Sets.	hair cosmetic products
51% Ownership TLL Parenterals Limited: Dedicated manufacturing arm for injectable pharmaceutical products, including ampoules and vials.	under the "YES" brand.

The Companys market access
continued to expand. As on
March 31, 2026, the Company
had 1,091 export-market
products registered and 2,534
registrations in process, a
presence across 46 countries.

The Companys growth
strategy centres on continuous
investment in product
registrations, expansion of
intellectual-property and brand
registrations, strengthening of
the supply chain, building of
sales and marketing capability
in key markets, and broadening
of the product portfolio in a
clustered, market-by-market
manner. Guided by its vision
of becoming a leading global
pharmaceutical player through
quality, affordability, and
reliability, the Company remains
focused on capitalising on
emerging opportunities while
managing the external risks
described above.

Segment-Wise
or Product-Wise
Performance

Consistent with the nature of
its operations, the Company
treats its business as a
single operating segment,
the manufacture and sale
of pharmaceutical and
allied healthcare products,
and accordingly reviews
performance on a product-wise
and market-wise basis.

By product category, tablets
remained the largest
contributor in FY26 at
approximately 67% of revenue,
followed by capsules at around
30%. Syrups, suspensions,
and oral-care and ointment
products together made up the
balance, at close to 1% each.

The product mix has stayed
broadly stable over recent
years, with tablets consistently
the leading category. The
Company continues to widen
its offering, which now
spans 3,625 products, by

adding new formulations and
therapeutic categories.

By market, the revenue profile
shifted materially during the
year. The domestic business
emerged as a key growth driver,
rising to approximately 49%
of revenue from 30% in FY25,
while exports contributed the
remaining 51%. Within exports,
Asia became the largest
destination at roughly 57%
of export revenue, followed
by Africa at 25% and South
America at 17%, a change from
FY25 when South America led.
This rebalancing toward the
domestic market and toward
Asia reflects the Companys
widening sales and marketing
reach and its growing base of
product registrations across
these markets.

FY26 Financial
Performance

On a consolidated basis,
Revenue from Operations grew
48% to Rs.129.0 crore from Rs.87.0
crore in FY25, taking the Group
past Rs.100 crore for the first
time. EBITDA rose 89% to Rs.28.1
crore from Rs.14.9 crore and the
EBITDA margin expanded 470
basis points to 21.8%. Cost of
materials rose 68% to Rs.76.5
crore against 48% revenue
growth, taking gross margin
down 690 basis points to
40.7%, but this was more than
offset by operating leverage
in overheads, with employee
benefits expense down 11% to
Rs.10.8 crore and other expenses
down 5% to Rs.13.7 crore.

Finance costs were broadly flat
at Rs.4.1 crore and depreciation
and amortisation rose 10% to
Rs.6.1 crore. Profit before tax
doubled to Rs.27.2 crore from
Rs.13.6 crore, and profit after
tax rose 84% to Rs.19.3 crore
from Rs.10.5 crore, lifting the
PAT margin 291 basis points to
15.0%.

On a standalone basis, revenue
from operations crossed
Rs.100 crore for the first time,
at Rs.101.9 crore, up 50%, with

EBITDA of Rs.24.3 crore and
profit after tax of Rs.18.1 crore.
Earnings per share improved
to Rs.15.73 from Rs.11.35. The
second half of the year was the
strongest on record. A notable
feature of the year was the
changing revenue mix. The
domestic business emerged
as a key growth driver, rising to
approximately 49% of revenue
from 30% in FY25, with exports
at around 51%.

SWOT Analysis

Strengths

-Hybrid manufacturing model
that combines own and
contract manufacturing,
supporting flexible and
capital-efficient scaling.

-Wide and growing market
access, with 1,091 export-
market products registered
and 2,534 registrations in
process across 46 countries.

-Diversified portfolio of 3,625
products across multiple
therapeutic areas, extended
into herbal, cosmetic, and
medical-device categories
through subsidiaries.

-Consistent track record of
revenue and profit growth,
with healthy margins.

Weaknesses

-Modest scale relative
to large, established
pharmaceutical peers.

-Margins are sensitive to shifts
in product and market mix;
the EBITDA margin eased

to 27% in FY26 from 29% a
year earlier.

-Working-capital
intensity, with a sizeable
receivables book linked to
international distribution.

Opportunities

-Continued scaling of the
domestic business, which
grew strongly during

the year.

-Conversion of the large
registration pipeline into
revenue across new markets.

-Additional capacity from
subsidiaries and new
facilities coming on stream.

-Broadening into new
formulations and therapeutic
categories, including
molecules going off-patent.

Threats

-United States tariff
developments and drug-
pricing policy proposals
affecting export markets.

-Foreign-exchange
volatility, given significant
export exposure.

-Competitive and pricing
pressure in generic and
nutraceutical markets.

-Evolving regulatory and
compliance requirements
across multiple jurisdictions.

Outlook

Looking ahead, the Company
maintains a constructive but
measured outlook. Its ongoing
projects across the parent
company and its subsidiaries,
together with operational
initiatives now taking effect,
provide a foundation for
continued growth, and it will
pursue expansion through
a balanced mix of organic

and inorganic initiatives. At
the same time, the external
environment carries some
headwinds, including West Asia
crises, currency volatility, and
the possibility that a stronger
domestic mix and input costs
continue to weigh on margins
relative to the export-led model.
With continued investment
in product registrations, an
expanding portfolio, additional
manufacturing capacity, and
a strengthening supply chain,
the Company considers itself
well positioned to pursue
sustainable growth while
managing these risks.

Key Financial Ratios (Consolidated)

Particulars	FY26	FY25	% Variance	Reasons
Current Ratio	1.59	1.69	(5.93%)	No Major Variance
Debt Equity Ratio	1.24	1.24	0.17%	No Major Variance
Debt Service Coverage Ratio	3.35	2.74	22.35%	Due to increase in NPAT during the year
Return on Equity Ratio	0.31	0.22	40.89%	Due to increase in NPBT during the year
Inventory Turnover Ratio	3.99	4.26	(6.36%)	No Major Variance
Trade Receivable Turnover Ratio	2.55	4.23	(39.79%)	Due to increase in Average Trade Receivables & increase in business
Trade Payable Turnover Ratio	2.78	4.78	(41.93%)	Due to increase in Average Trade Payables & increase in business
Net Capital Turnover Ratio	2.50	2.36	(5.81%)	No Major Variance
Net Profit Ratio	0.15	0.12	24.08%	Due to increase in NPAT during the year
Q Return on Capital Employed	0.21	0.15	33.81%	Due to increase in EBIT
. Return on Investment k	0.31	0.22	40.89%	Due to increase in NPBT during the year

Risks and Concerns

-Project Execution Risk: As the Company
scales manufacturing capacity through its
subsidiaries and new facilities, it is exposed
to execution risk, including possible cost
overruns, delays, or resource constraints that
could affect timelines and returns.

-Foreign Exchange Risk: A significant share
of revenue is earned in foreign currency,

so exchange-rate movements can affect
margins, cash flows, and competitiveness in
international markets.

-Credit and Receivables Risk: A large part of
the business is transacted with international
distributors and B2B partners and delayed
or non-recovery of receivables could affect
working capital and profitability.

-Competition and Pricing Risk: The Company
operates in competitive generic and
nutraceutical markets where pricing pressure
and new entrants could affect realisations
and market share.

Regulatory and Compliance Risk:

Operating across multiple regulatory
jurisdictions exposes the Company
to evolving standards and approval
requirements, non-compliance with
which could lead to delays, added costs, or
restrictions on specific markets.

Intellectual Property Risk: Protecting the
Companys brands, product registrations,
and know-how is important to sustaining its
competitive position, and any infringement
or dispute could affect its market standing.

Supply-Chain Risk: Operations depend on
the timely availability and reliability of key
raw materials and suppliers, and disruption
from geographic concentration or external
events could affect production.

Internal Control
Systems and Their
Adequacy

Trident Lifeline Limited
maintains a robust internal
control framework designed
to support efficient operations
and safeguard organisational
assets. The system comprises
comprehensive policies,
procedures, and practices
intended to prevent fraud,
ensure accurate financial
reporting, and maintain
compliance with applicable
regulation. Regular risk
assessments and systematic
internal audits are conducted
to identify improvement
opportunities and confirm
compliance, and findings
are reviewed by the Audit
Committee and the Board on a
periodic basis. As the Company
scales across a growing set of
subsidiaries and manufacturing

sites, controls are being
extended and standardised
across the group. By fostering
a culture of ethics and
accountability, the Company
sustains stakeholder confidence
and upholds its standing in
the industry.

Human Resources

Trident Lifelines performance
rests on the commitment and
expertise of its people. The
Company prioritises a working
environment that supports skill
development and engagement,
which in turn aids retention and
consistent execution. Its sales
and marketing network spans
multiple countries, enabling
efficient management of an
export-focused and increasingly
domestic operation. Continued
investment in people underpins
the Companys foundation for
sustainable growth.

Cautionary

Statement

Statements in the Management
Discussion and Analysis and
other parts of the report
describing the Companys
objectives, projections,
estimates and expectations
may be forward-looking
statements. Actual results
may differ materially from
those expressed or implied
due to various risks and
uncertainties. Important
factors that could make a
difference to the Companys
operations include economic
and political conditions in India
and other countries, in which
the Company may operate.
Other factors that may impact
the Companys operations
include volatility in interest
rates, changes in government
regulations and policies, tax
laws, statutes, and other
incidental factors.